Log in

DBV TECHNOLOGIE/S Stock Price, News & Analysis (NASDAQ:DBVT)

$6.75
-0.06 (-0.88 %)
(As of 10/14/2019 06:00 AM ET)
Today's Range
$6.65
Now: $6.75
$6.88
50-Day Range
$6.70
MA: $9.09
$10.30
52-Week Range
$3.60
Now: $6.75
$20.10
Volume541,814 shs
Average Volume498,221 shs
Market Capitalization$407.16 million
P/E RatioN/A
Dividend YieldN/A
Beta1.8
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DBVT
CUSIPN/A
Phone33-1-55-42-78-78

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.17 million
Book Value$2.41 per share

Profitability

Miscellaneous

Employees244
Market Cap$407.16 million
Next Earnings DateN/A
OptionableOptionable

Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.


DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions

What is DBV TECHNOLOGIE/S's stock symbol?

DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT."

How were DBV TECHNOLOGIE/S's earnings last quarter?

DBV TECHNOLOGIE/S (NASDAQ:DBVT) announced its earnings results on Thursday, March, 26th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History.

What price target have analysts set for DBVT?

9 analysts have issued 12-month price objectives for DBV TECHNOLOGIE/S's stock. Their forecasts range from $5.25 to $30.00. On average, they anticipate DBV TECHNOLOGIE/S's share price to reach $15.28 in the next year. This suggests a possible upside of 126.4% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S.

What is the consensus analysts' recommendation for DBV TECHNOLOGIE/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DBV TECHNOLOGIE/S.

What are Wall Street analysts saying about DBV TECHNOLOGIE/S stock?

Here are some recent quotes from research analysts about DBV TECHNOLOGIE/S stock:
  • 1. According to Zacks Investment Research, "DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. " (8/6/2019)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on DBVT shares after the company provided its 4Q18 business and financial update. We revise our model accordingly. As we indicated in our AAAAI recap/KOL dinner note, while the ICER analysis evaluating the cost effectiveness of peanut immunotherapies could pose a headwind for both DBVT and AIMT (Hold, $25.48), we do think the risk/reward for DBVT is probably more favorable at these levels if management is able to re-file its BLA on time in 3Q19, gain BLA acceptance from the FDA and its Adcom is eventually positive. With that said, we remain on the sidelines for now until management executes on its near-term regulatory initiatives and addresses its current capital overhang. We maintain our Hold rating and $10 target price." (3/6/2019)

Has DBV TECHNOLOGIE/S been receiving favorable news coverage?

News coverage about DBVT stock has been trending negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. DBV TECHNOLOGIE/S earned a news impact score of -2.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for DBV TECHNOLOGIE/S.

Who are some of DBV TECHNOLOGIE/S's key competitors?

What other stocks do shareholders of DBV TECHNOLOGIE/S own?

Who are DBV TECHNOLOGIE/S's key executives?

DBV TECHNOLOGIE/S's management team includes the folowing people:
  • Dr. Pierre-Henri Benhamou, Co-Founder & Non-Exec. Chairman (Age 64)
  • Mr. David Schilansky, Deputy CEO & CFO (Age 44)
  • Dr. Laurent Martin, Chief Devel. Officer (Age 52)
  • Mr. Daniel Tassé, CEO & Director (Age 59)
  • Mr. Bertrand Dupont, Co-Founder & CTO (Age 67)

How do I buy shares of DBV TECHNOLOGIE/S?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is DBV TECHNOLOGIE/S's stock price today?

One share of DBVT stock can currently be purchased for approximately $6.75.

How big of a company is DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S has a market capitalization of $407.16 million and generates $17.17 million in revenue each year. The company earns $-196,140,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis. DBV TECHNOLOGIE/S employs 244 workers across the globe.View Additional Information About DBV TECHNOLOGIE/S.

What is DBV TECHNOLOGIE/S's official website?

The official website for DBV TECHNOLOGIE/S is http://www.dbv-technologies.com/.

How can I contact DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected]


MarketBeat Community Rating for DBV TECHNOLOGIE/S (NASDAQ DBVT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  321 (Vote Outperform)
Underperform Votes:  340 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel